Boston, MA 的 淋巴瘤 臨床試驗
33 項針對 淋巴瘤 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
招募中1 期
- Beth Israel Deaconess Medical Center - Research, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
招募中2 期
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
招募中
- Mass General Hospital, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
招募中
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
招募中2 期
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
招募中1/2 期
- Research Site, Boston
- Research Site, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
招募中3 期
- Research Site, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
招募中4 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
The CARDIOPROTECT Trial
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Dana Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
招募中1/2 期
- Call for Information (Investigational Site 0026), Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
招募中1/2 期
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
招募中
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
招募中
- Massachusetts General Hospital Cancer Center, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
招募中
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- Dana-Farber Cancer Institute, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
Odronextamab in Low Tumor Volume Advanced FL
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
招募中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
招募中1/2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
招募中1/2 期
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
招募中2 期
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
招募中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
其他城市的 淋巴瘤 試驗
- Houston, TX34 項研究
- New York City, NY33 項研究
- Washington, DC23 項研究
- Baldwin Park, CA21 項研究
- Chicago, IL20 項研究
- Durham, NC17 項研究
- St. Louis, MO15 項研究
- Philadelphia, PA15 項研究
- Cleveland, OH14 項研究
- Edison, NJ12 項研究
- Atlanta, GA12 項研究
- Seattle, WA12 項研究
Boston 的其他研究
- 乳癌111 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）86 項研究
- 大腸直腸癌63 項研究
- 轉移性癌症63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。